Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Phase 3
400
about 21 years
19+
1 site in NE
About this study
This trial is testing a treatment for rheumatoid arthritis (RA) using different medications called DMARDs. The goal is to find out what factors help predict how well people respond to these medications. Participants will receive a starting dose of one or more DMARD medications, which may be adjusted by the doctor as needed.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Abatacept
- 2.Take Adalimumab
- 3.Take Azathioprine
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
abatacept, adalimumab (Monoclonal antibody; blocks TNF-alpha to reduce inflammation), azathioprine (Antimetabolite; inhibits DNA synthesis in immune cells), baricitinib, certolizumab pegol, etanercept (TNF inhibitor (fusion protein capturing TNF-alpha)), golimumab, hydroxychloroquine (Antimalarial; increases pH in parasite)
injection, intravenous, oral (Oral Tablet), oral, infusion, oral (Delayed Release Oral Tablet)
Immune